Fig. 6

FITC-Dextran (4 kDa) tracer dye clearance from the brain parenchyma into the cerebrospinal fluid, blood and deep cervical lymph nodes. A) Schematic timeline of tracer infusion into the brain parenchyma along the anterior/posterior (A/P), medial/lateral (M/L) and dorsal/ventral (D/V) axes and the collection of blood, cerebrospinal fluid (CSF) and tissue samples. B) Quantification of tracer concentrations in CSF from the Hspg2^+/+ (n = 7) and Hspg2^∆3∆91 (n = 7) mice. C, D) Tracer concentration or its change relative to baseline in blood samples in the Hspg2^+/+ (n = 7) and Hspg2^∆3∆91 (n = 7) mice. E) Deep cervical lymph nodes (dcLNs) collected from Hspg2^+/+ and Hspg2^∆3∆91 mice 60 min after FITC-dextran 4 kDa injection. F, G) Quantification of tracer intensity and size of dcLNs in Hspg2^+/+ (n = 7) and Hspg2^∆3∆91(n = 7) mice. Scale bar, 500 μm (E). The statistical tests used were the Mann-Whitney unpaired two-tailed t-test (B, G), the unpaired two-tailed t-test with Welch’s correction (F) and 2-way ANOVA followed by Sidak’s post-hoc test (C, D). ns, non-significant. Mean ± SEM